EUCTR2010-023749-30-IT进行中（未招募）1 期
Studio PKCT - Pharmacokinetics of chemotherapy when given concurrently with antiretroviral (Protocol no. CSL01).
FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR0 个研究点目标入组 3 人开始时间: 2012年3月13日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 3
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Age> 18 years
- •-HIV-infection in treatment for at least 1 week with antiretroviral therapy based on two nucleoside analogues and a protease inhibitor (with or without a booster dose of ritonavir) or with a nucleoside reverse transcriptase inhibitor
- •-NHL that requires CT as (R) HD CHOP or HD requiring CT as ABVD
- •-HIV-RNA <50 copies / ml.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •-previous failure to raltegravir
- •-documented resistance to raltegravir
- •-raltegravir can't be associated with at least 2 drugs active against HIV in the class of nucleoside analogues
- •-pregnant or nursing.
研究者
相似试验
已完成
1 期
A single injection dose study of DUR-928 in patients with impaired kidney function and healthy volunteersImpaired Kidney Function – stage 3 and 4Renal and Urogenital - Kidney diseaseACTRN12616000389404George Clinical Pty Ltd18
招募中
不适用
Pharmacokinetics of chemotherapeutic agents in children’s oncologyCancerNL-OMON25390Princess Maxima Center for pediatric oncology270
进行中（未招募）
不适用
A DOSE FINDING PHARMACOKINETIC STUDY OF THE TUMOUR TARGETING HUMAN L19IL2 MONOCLONAL ANTIBODY CYTOKINE FUSION PROTEIN IN PATIENTS WITH ADVANCED SOLID TUMOURSsolid tumors and renal cell carcinomaMedDRA version: 6.1Level: HLTClassification code 10038408EUCTR2005-002716-16-ITPHILOGEN S.P.A.30
已完成
1 期
Pharmacokinetic/Pharmacodynamic (PK/PD) Study to Evaluate Adrenaline (Epinephrine) Exposure Following Intramuscular Administration of Fastjekt® Auto-Injector (0.3 mg; Mylan) in Adult Volunteers with Varying Skin to Muscle Distance (STMD) in the Thighhealthy volunteersDRKS00011263Mylan Pharmaceuticals Inc.35
未知
1 期
TK-FT Pharmacokinetic Study (Patients)Breakthrough cancer painJPRN-jRCT2080220502TEIKOKU SEIYAKU CO., LTD.15